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Abstract
 .Thermostable direct hemolysin TDH , a pore-forming toxin produced by Vibrio parahaemolyticus, is cytotoxic to Rat-1,
a fibroblast cell line derived from rat embryo. Through mutagenesis of Rat-1 with nitrosoguanidine, we established a mutant
cell line, MR-T1. MR-T1 was over 200 times more resistant to the cytotoxic activity of TDH than Rat-1. TDH increased
membrane permeability of Rat-1 but not of MR-T1. Binding analysis showed that, while being able to bind to Rat-1, TDH
failed to bind to MR-T1, indicating that MR-T1 is deficient in the putative receptor for TDH. Somatic hybrid cells between
Rat-1 and MR-T1 were similarly sensitive to TDH as Rat-1. Moreover, TDH could bind to the hybrid cells as well as to
Rat-1 cells. These results indicate that MR-T1 is promising for complementation cloning of a gene related to the putative
receptor for TDH.
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1. Introduction
Vibrio parahaemolyticus is a food-borne
pathogenic bacterium that causes gastroenteritis.
 .Thermostable direct hemolysin TDH is considered
w xto be a major virulence factor of this organism 1 .
TDH has multiple biological activities such as
hemolytic activity, cardiotoxicity, cytotoxicity and
) Corresponding author. Fax: q81 6 8798277; E-mail:
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w xenterotoxicity 1 . Although there have been several
w xreports on the cytotoxcity of TDH 2–4 , the mode of
action of TDH upon target cells is still poorly under-
stood. TDH has been previously suggested to be a
w xpore-forming toxin 5 , however, it is unknown
whether this toxin initially interacts with receptors
prior to insertion into the lipid bilayer of the target
cell membrane and pore-formation. G gangliosidesT1
have previously been suggested as the receptor for
w x w xTDH 6–8 . However, this is controversial 9 and
further experimental evidence is necessary to clarify
the issue.
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In research on the cytotoxic action of toxins, com-
parison of differences of toxin effects on toxin-re-
sistant and toxin-sensitive cell lines have been widely
employed and have provided valuable information
w x10–12 . A similar approach is to isolate mutant cell
lines resistant to toxins and their application in func-
w xtional analysis of the target molecules 13–16 . In
order to elucidate the mechanism underlying the ac-
tion of TDH on target cells, we attempted to isolate
TDH-resistant cell lines through chemical mutagene-
sis. In this study, we obtained a mutant cell line,
MR-T1, which showed resistance to TDH. MR-T1
was shown to be deficient in the putative receptor for
TDH and promising in complementation cloning of a
gene related to the receptor.
2. Materials and methods
2.1. Cell lines and culture
All the cell lines used were either from the Ameri-
can Type Culture Collection or were the kind gifts
from Japanese Cancer Research Sources Bank. All
the fibroblast and epithelial cells were grown in
Dulbecco’s modified Eagle’s medium DMEM,
.Nikken Biomedical Laboratory, Kyoto, Japan sup-
 .plemented with 5% fetal calf serum FCS . Cells
originated from immune system were cultured in
 .RPMI 1640 medium Biken, Osaka, Japan supple-
mented with 10% FCS. Cells were cultured in a
humid atmosphere of 95% air and 5% carbon dioxide
at 378C.
2.2. Toxins
TDH and R7, a mutant toxin of TDH, were puri-
w xfied as previously described 17 .
2.3. Chemical mutagenesis
Rat-1 fibroblast cells were grown in 100 mm Petri
dishes to approx. 60% confluence and then treated
with 150 mgrml N-methyl-N X-nitro-N X-nitrosoguani-
 .dine NTG for 16 h. After removing NTG and
washing with serum-free DMEM, the surviving cells
were incubated for more than 2 wk for recovery.
Selection of mutant cells resistant to TDH was con-
ducted by reseeding and treatment with medium con-
taining 10 mgrml TDH for 8 h. After removing
TDH, treated cells were incubated in fresh medium
for more than 2 wk to observe whether any clone
appeared.
2.4. Cytotoxicity assay
TDH cytotoxicity was measured using a cell count-
 .ing kit Dojindo, Fukuoka, Japan according to a
w xpreviously reported method 4 except that monolayer
of cells instead was treated with TDH in DMEM-5%
FCS.
2.5. Measurement of the influx of Ca2q and propid-
ium iodide
2q  .The influx of Ca and propidium iodide PI into
cells was measured using a previously described
w xmethod 4 .
2.6. Binding assay
5 mgrml of TDH or R7 was allowed to interact
6 with 5=10 cells suspended in 200 ml PBS phos-
 .phate buffered saline, 0.01 M KH PO rNa H-2 4 3 2
 . .PO , 0.9% NaCl for 1 h at 378C. To remove the4 3
free unbound toxins, the cells were washed with 1 ml
PBS for 5 times by centrifugation at 800=g for 5
min. The cell pellets were then solubilized in 100 ml
 .of 2% sodium dodecyl sulfate SDS solution and
mixed with sodium dodecyl sulfate-polyacrylamide
 .gel electrophoresis SDS-PAGE sample buffer fol-
lowed by heating at 1008C for 10 min and 10 ml was
w xloaded for electrophoresis 18 . Cell-bound toxins
were detected by the Western blotting using anti-TDH
w xserum 19 .
2.7. Transfection and selection of transfectants
Parent Rat-1 cells and mutant MR-T1 cells were
conferred either hygromycin-resistant or neomycin-
resistant through DNA transfection as described pre-
w x w xviously 20 with plasmid vectors, pHyg 21 and
w xpSV2-neo 22 , respectively. Hygromycin-resistant
w xRat-1 pHyg cells were selected by using 200 mgrml
hygromycin B and neomycin-resistant MR-
w xT1 pSV2neo cells were selected by using 500 mgrml
 .G418 a neomycin analogue .
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2.8. Cell fusion
w x w xRat-1 pHyg cells and MR-T1 pSV2neo cells were
w xfused as previously described 23 . Somatic hybrid
cells were selected using a medium containing both
200 mgrml hygromycin B and 500 mgrml G418
and pooled for analysis.
3. Results
3.1. Susceptibility of cell lines to TDH
Before isolating the TDH-resistant cell lines, we
screened a variety of cell lines available in our
laboratories to examine their susceptibility to TDH.
As shown in Table 1, different cell lines displayed
varying susceptibility to TDH: the maximum value of
 .50% cytotoxic dose CD was 200 times the mini-50
mum. This indicated that TDH action was dependent
on the target cells. These results prompted us to start
the isolation of TDH-resistant mutant cell lines from
Rat-1, the most sensitive cell line.
3.2. Isolation of TDH-resistant mutant cell lines
NTG is an alkylating reagent which usually causes
point mutation in DNA. In chemical mutagenesis,
Table 1
TDH-sensitivity of cell lines from various sources
Cell line Origin CD50
 .mgrml
Rat-1 rat embryo 0.5
HeLa human cervix 2
Intestine 407 human embryorjejunum-ileum 5
Caco-2 human colon carcinoma 5
HEp-2 human larynx 5
CV-1 monkey kidney 5
COS-1 monkey kidney 5
K562 human erythroleukemia 5
HL-60 human promyelocytic leukemia 10
WI138VA13 human lung 20
C127I mouse mammary 20
NIHr3T3 mouse embryo 20
Ag8 mouse myeloma 40
Hybridoma mouse Ag8 q B cell 40
CHO hamster ovary 100
Fig. 1. Cytotoxicity of TDH on Rat-1 and MR-T1 cells. Cytotoxi-
city of TDH was measured using a cell counting kit. I, Rat-1
cells; ^, MR-T1 cells.
doses and interaction times of mutagens, which cause
70%–90% of cells to die, were usually employed
w x24,25 . Treatment with 150 mgrml of NTG for 16 h
was found to cause death of 70%–90% of Rat-1
cells. Consequently, we set up these conditions for
the mutagenesis of Rat-1 cells. For selection of
TDH-resistant mutant cells, we used medium contain-
ing 10 mgrml TDH. Under this regime of mutagene-
sis and selection, we conducted rounds of experi-
ments until we finally obtained a clonal cell line
resistant to TDH, which we named MR-T1.
3.3. Resistance of MR-T1 to the cytotoxic acti˝ity of
TDH
To quantitatively determine the resistance of MR-
T1 to TDH, we conducted cytotoxicity assays. After
growth into a monolayer, cells were challenged with
various doses of TDH in medium and incubated for 1
h. The cell viability was quantified by a cell counting
kit.
As shown in Fig. 1, TDH was cytotoxic to Rat-1
cells in a dose dependent manner and at 1 mgrml
caused 50% loss of viability. However, even at 100
mgrml, the highest concentration available for chal-
lenge, TDH caused little detectable loss of viability
of MR-T1 cells. In other words, the mutant cell line
was over 200 times more resistant to TDH than
susceptible parent cells.
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Fig. 2. Membrane-active effects of TDH. Cells were treated with
5 mgrml TDH. The influx of Ca2q, using Fluo 3 as the indicator,
and the influx of PI were measured by FACScan. A and B,
Ca2q-influx; C and D, PI-influx. A and C, cells not treated with
TDH; B and D, cells treated with TDH.
3.4. Membrane-acti˝e effects of TDH on Rat-1 and
MR-T1 cells
TDH has been shown to increase membrane per-
meability of both erythrocytes and a cell line, Intes-
 .tine 407, inducing influx of propidium iodide PI
2q w xand Ca 4,17 . We observed whether TDH had
such effects on Rat-1 and MR-T1 cells.
As shown in Fig. 2, TDH caused influxes of both
Ca2q and PI into Rat-1 cells. However, no influx of
Ca2q and PI into MR-T1 cells was observed. This
indicates that, while increasing the membrane perme-
ability in Rat-1, TDH can not induce such effects in
MR-T1.
3.5. Binding of TDH to Rat-1 and MR-T1 cells
We investigated whether the resistance of MR-T1
to TDH might be due to any deficiency at the binding
step. R7 is a mutant toxin of TDH that has retained
the ability to bind to erythrocytes while it shows no
w xevidence of postbinding activities 17 . Here we ana-
lyzed whether TDH and R7 could bind to Rat-1 and
MR-T1 cells.
The toxins were separately allowed to interact with
Rat-1 and MR-T1 cells. After stringent washing, any
toxins that might have bound to the cells were lyzed
out with 2% SDS and detected by Western blotting.
As shown in Fig. 3, both toxins were detected from
Fig. 3. Binding analysis. 5 mgrml toxins were allowed to interact
with Rat-1 and MR-T1 cells. Toxins bound to cells were solubi-
lized in 2% SDS, which were then detected by western blotting.
 .Lane 1, purified TDH 1 ng ; Lane 2 and 3, TDH bound to Rat-1
and MR-T1 cells; Lane 4 and 5, R7 bound to Rat-1 and MR-T1
cells.
Rat-1 cells whereas neither could be recovered from
MR-T1 cells. This indicates that TDH and R7 can
bind to Rat-1 cells whereas they can not bind to
MR-T1 cells. These results suggest that MR-T1 is
deficient in the putative receptor for TDH and conse-
quently gets resistant to TDH. The results also sug-
gest that, in MR-T1, a mutation occurred in a gene
which is related to the receptor.
3.6. Fusion between Rat-1 and MR-T1 cells and the
sensiti˝ity of hybrid cells to TDH
To investigate whether the mutation in MR-T1
related to the receptor is dominant or recessive, we
performed cell fusion experiments between Rat-1 and
MR-T1.
We transfected Rat-1 with pHyg carrying hy-
gromycin-resistance gene and MR-T1 cells with
pSV2-neo carrying neomycin-resistance gene. The
w xresultant hygromycin-resistant Rat-1 pHyg and
w xneomycin-resistant MR-T1 pSV2neo were fused by
polyethylene glycol 1500 PEG 1500, Boehringer-
w xFig. 4. Cytotoxic activity of TDH on hybrid cells. I, Rat-1 pHyg
w xcells; ‘, hybrid cells; ^, MR-T1 pSV2neo cells.
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Fig. 5. Binding of TDH and R7 to hybrid cells. The binding
assay was conducted as described in legend of Fig. 3. Lane 1,
 . w xpurified TDH 1 ng ; Lane 2 to 4, TDH bound to Rat-1 pHyg ,
w xhybrid and MR-T1 pSV2neo cells; Lane 5 to 7, R7 bound to
w x w xRat-1 pHyg , hybrid and MR-T1 pSV2neo cells.
.Mannheim, Germany . Hybrid cells were selected
with both hygromycin and neomycin and pooled.
Sensitivity of the hybrid cells to TDH was compared
with that of their parent cells by cytotoxicity assay.
As shown in Fig. 4, hybrid cells were similarly
w xsensitive to cytotoxic activity of TDH as Rat-1 Hyg
w xcells while MR-T1 pSV2neo was resistant to TDH.
This result indicates that the mutation in MR-T1 is a
recessive one and could be complemented by cDNA
from Rat-1 cells.
3.7. Binding of TDH to hybrid cells
We analyzed possible restoration of the binding of
TDH to hybrid cells. As shown in Fig. 5, both TDH
w xand R7 were detected from both Rat-1 Hyg and
hybrid cells while failed to be detected from MR-T1
cells. This indicates that TDH can bind to hybrid
cells and suggests that restoration of the binding of
TDH to cells confers their sensitivity to TDH.
4. Discussion
TDH shows target cell specificity and the different
sensitivity of cells to TDH could vary within a range
 .of 200 folds Table 1 . This indicates that determi-
 .nant s on target cells are important for cytotoxic
activity of TDH.
Our success in isolating a mutant cell line resistant
 .to TDH, MR-T1, indicates that the mutation s oc-
curred in MR-T1 caused deficiency in certain
 .molecule s on target cells, which leads to resistance
 .to TDH. Deficiency in such molecule s may also
lead to unresponsiveness of MR-T1 to effects of
TDH such as increase of membrane permeability
 2q .  .Ca - and PI-iflux Fig. 2 .
As TDH could not bind to MR-T1 cells Figs. 3
.and 5 , the simplest interpretation is that a mutation
in MR-T1 caused deficiency in the function of the
receptor for TDH. This deficiency is quite probably
responsible for the resistance of MR-T1 to TDH.
Taking together, our results suggest that a receptor
existing on target cells is necessary for TDH to
accomplish its cytotoxic effects on Rat-1 cells. There-
w xfore, as a pore-forming toxin 5 , TDH seems to
initially interact with specific receptors, induce pore-
formation and final cytolysis, as most pore-forming
w xtoxins do 26 .
R7, a mutant toxin of TDH, is deficient in
hemolytic activity but retains the ability to bind to
erythrocytes. Another interesting characteristic of R7
is that it has inhibitory effect on the hemolysis by
TDH. This inhibition is most probably due to the
w xcompetition of R7 with TDH for its receptor 17 . R7
also has inhibitory effect on cytotoxic effects of TDH
 .on Rat-1 cells data not shown , suggesting that R7
competes with TDH for its receptor on nucleated
cells as well. This was supported by the coincidence
that mutation in MR-T1 resulted in loss of binding of
 .both TDH and R7 Fig. 3 . All these data suggest that
R7 would recognize the receptor for TDH and inhibit
the action of TDH by competition. We noticed that,
during binding assay, the band of TDH was weaker
than that of R7 when detected from Rat-1 or fusion
 .cells Figs. 3 and 5 . We explain this phenomenon as
following. In binding assay, during washing the cell
from free toxins by vortexing and low speed centrifu-
gation, loss of cell-bound TDH is likely to happen
because TDH causes membrane blebbing and vesicu-
w xlation 4 . In contrast, this is unlikely to happen in
case of R7 since it does not cause any damaging
effects on cells.
 .TDH-related hemolysin TRH is considered to be
another virulence factor of certain strains of V. para-
w xhaemolyticus 1 . TRH shares about 67% homology
w xwith TDH on amino acid level 27 . Nevertheless, as
far as hemolytic activity is concerned, TRH shows a
different spectrum of specificity on target erythro-
w xcytes as compared with TDH 28 . We are interested
 .in whether there are overlapping pathway s on target
cells involved in action of TDH and TRH. Using
MR-T1, we found that Rat-1 was sensitive while
MR-T1 was resistant to TRH to a similar degree as
TDH and, what is more, cytotoxicity of TRH on
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 .Rat-1 cells could be inhibited by R7 data not shown .
This suggests that MR-T1 is deficient in the common
molecule which is necessary for cytotoxicity of TDH
and TRH. The present study showed that the molecule
would quite probably be the receptor for these toxins.
These results suggest that TDH and TRH share a
common molecule as a receptor. If this is the case,
the distinct target specificity of these two toxins
could be attributed to their distinct postbinding path-
 .way s .
Deficiency in receptor for TDH in MR-T1 should
be caused by the mutation of a gene. This gene may
be directly related to the receptor by encoding the
receptor itself or a part of a receptor complex. Also
possibly, this gene may be indirectly related to the
receptor by encoding a protein which is involved in
the biosynthesis of the receptor. Our final purpose is
expression cloning of this gene. Before doing this, it
is important to determine whether the mutation in
MR-T1 related to receptor is a dominant or recessive
one. If it is a dominant one, we must clone the
mutated gene from MR-T1 into Rat-1 cells and select
the TDH-resistant cell clones. In contrast, if it is a
recessive one, we should clone the original gene from
Rat-1 cells into MR-T1 cells and select the TDH-sen-
sitive cell clones. In this study, we employed cell
fusion techniques and showed that the sensitivity to
TDH could be restored in MR-T1 cells by fusion
 .with Rat-1 cells Fig. 4 . This restoration of sensitiv-
ity seems to be due to restoration of a functional
 .receptor for TDH-binding in fusion cells Fig. 5 .
These results demonstrate that the mutation in MR-T1
is a recessive one and complementation cloning of
the gene is possible by introducing cDNA from Rat-1
to MR-T1. This work are presently ongoing in our
laboratory.
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